Browsing by author "Lopez, Juanita"
Now showing items 1-15 of 15
-
Adult brain tumour research in 2024: Status, challenges and recommendations.
Purshouse, K; Bulbeck, HJ; Rooney, AG; Noble, KE; Carruthers, RD; et al. (WILEY, 2024-04-01)In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government ... -
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap, TA; Krebs, MG; Postel-Vinay, S; El-Khouiery, A; Soria, J-C; et al. (AMER ASSOC CANCER RESEARCH, 2021-10-01)PURPOSE: This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients ... -
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Brown, JS; Sundar, R; Lopez, J (2018-02)The idea that chemotherapy can be used in combination with immunotherapy may seem somewhat counterproductive, as it can theoretically eliminate the immune cells needed for antitumour immunity. However, much preclinical ... -
Emerging biomarkers for PD-1 pathway cancer therapy.
Lim, JS; Sundar, R; Chénard-Poirier, M; Lopez, J; Yap, TA (2017-01)The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. ... -
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.
Falchook, G; Infante, J; Arkenau, H-T; Patel, MR; Dean, E; et al. (ELSEVIER, 2021-04-01)BACKGROUND: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. ... -
Immuno-oncology combinations: raising the tail of the survival curve.
Harris, SJ; Brown, J; Lopez, J; Yap, TA (2016-06)There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small ... -
Next Generation Cancer Vaccines-Make It Personal!
Terbuch, A; Lopez, J (2018-08-09)Dramatic success in cancer immunotherapy has been achieved over the last decade with the introduction of checkpoint inhibitors, leading to response rates higher than with chemotherapy in certain cancer types. These responses ... -
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Evans, TRJ; Dean, E; Molife, LR; Lopez, J; Ranson, M; et al. (2019-02)BACKGROUND:This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS:Eligible patients ... -
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Lopez, J; Lai-Kwon, J; Molife, R; Welsh, L; Tunariu, N; et al. (SPRINGERNATURE, 2023-09-21)BACKGROUND: The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates sphingomyelin synthase expression and regulates membrane-lipid composition and ... -
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Kristeleit, R; Evans, J; Molife, LR; Tunariu, N; Shaw, H; et al. (SPRINGERNATURE, 2020-08-03)BACKGROUND: BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents. METHODS: ... -
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.
Yap, TA; Winter, JN; Giulino-Roth, L; Longley, J; Lopez, J; et al. (AMER ASSOC CANCER RESEARCH, 2019-12-15)PURPOSE: Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. PATIENTS AND METHODS: This phase I study determined the safety, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of ... -
Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study.
Geva, R; Lopez, J; Danson, S; Joensuu, H; Peer, A; et al. (2019-05)PURPOSE:Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases; however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer ... -
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
O'Carrigan, B; Lim, JSJ; Jalil, A; Harris, SJ; Papadatos-Pastos, D; et al. (2018-10-15)Background Greater understanding of the molecular classification of breast cancer has permitted the development of rational drug design strategies. In a phase I clinical trial setting, molecular profiling with next-generation ... -
The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations.
Collins, DC; Chenard-Poirier, M; Lopez, JS (2018-01)Immunotherapy has led to a paradigm shift in the treatment of some malignancies, providing long-term, durable responses for a subset of patients with advanced cancers. Increasingly, research has identified links between ... -
To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.
Ameratunga, M; Kipps, E; Okines, AFC; Lopez, JS (2019-01)Dysregulation of cell division resulting in aberrant cell proliferation is a key hallmark of cancer, making it a rational and important target for innovative anticancer drug development. Three selective cyclin-dependent ...